预计到2032年,由于癌症病例和美国公司的合作,PDC市场年增长率为29%。 PDC market growth projected at 29% annually by 2032, driven by cancer cases and U.S. company collaborations.

全球类药物联合体 (PDC) 市场预计到2032年将以每年29%的速度增长,这得益于癌症病例的增加和PDC在向治疗中的有效性. The global peptide-drug conjugate (PDC) market is expected to grow at 29% annually by 2032, fueled by rising cancer cases and the effectiveness of PDCs in targeted treatments. 北美将引领这一增长, 在美国, 诺华和佩普提德林等公司之间 加强了合作。 North America will lead this growth, with the U.S. seeing increased collaborations among companies like Novartis and PeptiDream. PDC 将肽与强效药物相结合，以实现精确的肿瘤靶向，与其他疗法相比，具有体积更小、组织渗透性更好的优势。 PDCs, which combine peptides with potent drugs for precise tumor targeting, offer advantages like smaller size and better tissue penetration compared to other therapies.